The other assayed biomarkers followed the same trend but did not reach statistical significance: VCAM1 (253.60 ± 30.31 vs. 202.30 ± 32.08 ng/mL), MPO (14.02 ± 2.98 vs. 7.99 ± 1.06 ng/mL), PAI1 (14.30 ± 2.36 vs. 11.27 ± 2.16 ng/mL) and MMP9 (11.78 ± 2.43 vs. 6.07 ± 1.37 ng/mL). 3.3.
← all excerpts
Changes in High-Density Lipoproteins Related to Outcomes in Patients with Acute Stroke.
1
—
—